Diphtheria - Pipeline Review, H1 2017

Publisher Name :
Date: 23-May-2017
No. of pages: 68
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 4, 5, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Diphtheria - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diphtheria - Overview
Diphtheria - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diphtheria - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Diphtheria - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Boryung Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
GlaxoSmithKline Plc
Green Cross Corp
Indian Immunologicals Ltd
Kaketsuken KK
LG Chem, Ltd.
Prometheon Pharma LLC
Sanofi
Sanofi Pasteur SA
Serum Institute of India Ltd
Shantha Biotechnics Ltd
Zydus Cadila Healthcare Ltd
Diphtheria - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diphtheria vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTaP-IPV-HB-PRPT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-1107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diphtheria - Dormant Projects
Diphtheria - Discontinued Products
Diphtheria - Product Development Milestones
Featured News & Press Releases
Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Diphtheria, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Diphtheria - Pipeline by Biological E Ltd, H1 2017
Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Diphtheria - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2017
Diphtheria - Pipeline by Green Cross Corp, H1 2017
Diphtheria - Pipeline by Indian Immunologicals Ltd, H1 2017
Diphtheria - Pipeline by Kaketsuken KK, H1 2017
Diphtheria - Pipeline by LG Chem, Ltd., H1 2017
Diphtheria - Pipeline by Prometheon Pharma LLC, H1 2017
Diphtheria - Pipeline by Sanofi, H1 2017
Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2017
Diphtheria - Pipeline by Serum Institute of India Ltd, H1 2017
Diphtheria - Pipeline by Shantha Biotechnics Ltd, H1 2017
Diphtheria - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Diphtheria - Dormant Projects, H1 2017
Diphtheria - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diphtheria - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Diphtheria, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • 2015-2023 World Cefazolin Sodium Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 16-Jun-2018        Price: US 2800 Onwards        Pages: 104
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • 2015-2023 World Cefprozil Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 16-Jun-2018        Price: US 2800 Onwards        Pages: 111
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • 2015-2023 World Drugs for Vancomycin-Resistant Enterococcus Faecium Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 14-Jun-2018        Price: US 2800 Onwards        Pages: 98
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • Global Polymixin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 13-Jun-2018        Price: US 3480 Onwards        Pages: 128
    Polymyxins are antibiotics, with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. They are produced by nonribosomal peptide synthetase systems in Gram-positive bacteria such as Paenibacillus polymyxa and are selectively toxic for Gram-negative bacteria due to their specificity for the lipopolysaccharide molecule that exists within many Gram-negative outer membranes. At......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Polymixin Market 2018, Forecast to 2023
    Published: 13-Jun-2018        Price: US 4880 Onwards        Pages: 128
    Polymyxins are antibiotics, with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. They are produced by nonribosomal peptide synthetase systems in Gram-positive bacteria such as Paenibacillus polymyxa and are selectively toxic for Gram-negative bacteria due to their specificity for the lipopolysaccharide molecule that exists within many Gram-negative outer membranes. At......
  • Global Clotrimazole Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 07-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Clotrimazole is a white powdered pharmaceutical used for treatment of dermatological and gynaecological fungal infections. Clotrimazole was synthesised in 1969 firstly and its chemical name is 1-[(2-chloro-phenyl)(diphenyl)methyl]-1H-imidazole). Its molecular formula is C22H17ClN2 and the molecular weight is 344.8 g/mol.Clotrimazole is an inhibitor of ergosterol biosynthesis. It has many ecotoxicological properties in common with a range of fungicides used in agriculture. Clotrimazole is a broad......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Clotrimazole Market 2018, Forecast to 2023
    Published: 07-Jun-2018        Price: US 4880 Onwards        Pages: 135
    Clotrimazole is a white powdered pharmaceutical used for treatment of dermatological and gynaecological fungal infections. Clotrimazole was synthesised in 1969 firstly and its chemical name is 1-[(2-chloro-phenyl)(diphenyl)methyl]-1H-imidazole). Its molecular formula is C22H17ClN2 and the molecular weight is 344.8 g/mol.Clotrimazole is an inhibitor of ergosterol biosynthesis. It has many ecotoxicological properties in common with a range of fungicides used in agriculture. Clotrimazole is a broad......
  • Global Polymixin Market Research Report 2018
    Published: 01-Jun-2018        Price: US 2900 Onwards        Pages: 94
    This report studies the global Polymixin market status and forecast, categorizes the global Polymixin market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa). Polymyxins are antibiotics, with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt ......
  • United States Amoxicillin Market Report 2018
    Published: 01-Jun-2018        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Amoxicillin market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Amox......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs